Technical Analysis for ZLAB - Zai Lab Limited
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Gapped Down | Weakness | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -4.99% | |
Gapped Up | Strength | -4.99% | |
Up 3 Days in a Row | Strength | -4.99% | |
Up 4 Days in a Row | Strength | -4.99% | |
Oversold Stochastic | Weakness | -4.99% | |
Stochastic Buy Signal | Bullish | -3.69% | |
Up 3 Days in a Row | Strength | -3.69% | |
Gapped Down | Weakness | -3.69% | |
Oversold Stochastic | Weakness | -3.69% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 5% | about 14 hours ago |
Fell Below Lower Bollinger Band | about 14 hours ago |
Lower Bollinger Band Support | about 14 hours ago |
Down 1 ATR | about 14 hours ago |
Gapped Down (Full) | about 14 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2023
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases Omadacycline
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases Omadacycline
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 49.81 |
52 Week Low | 20.98 |
Average Volume | 416,627 |
200-Day Moving Average | 32.52 |
50-Day Moving Average | 26.23 |
20-Day Moving Average | 25.79 |
10-Day Moving Average | 24.97 |
Average True Range | 1.41 |
RSI (14) | 41.52 |
ADX | 10.28 |
+DI | 22.95 |
-DI | 30.31 |
Chandelier Exit (Long, 3 ATRs) | 25.41 |
Chandelier Exit (Short, 3 ATRs) | 26.92 |
Upper Bollinger Bands | 28.19 |
Lower Bollinger Band | 23.39 |
Percent B (%b) | 0.13 |
BandWidth | 18.61 |
MACD Line | -0.40 |
MACD Signal Line | -0.29 |
MACD Histogram | -0.1069 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 25.33 | ||||
Resistance 3 (R3) | 25.33 | 24.89 | 25.11 | ||
Resistance 2 (R2) | 24.89 | 24.56 | 24.89 | 25.03 | |
Resistance 1 (R1) | 24.45 | 24.35 | 24.23 | 24.44 | 24.96 |
Pivot Point | 24.01 | 24.01 | 23.90 | 24.01 | 24.01 |
Support 1 (S1) | 23.56 | 23.67 | 23.34 | 23.56 | 23.04 |
Support 2 (S2) | 23.12 | 23.46 | 23.12 | 22.97 | |
Support 3 (S3) | 22.68 | 23.12 | 22.89 | ||
Support 4 (S4) | 22.67 |